Minerva Updates on Phase 3 Trial for Roluperidone
Minerva Neurosciences announced ongoing Phase 3 trial (C19) for roluperidone with topline efficacy data expected in the second half of 2027, targeting negative symptoms of schizophrenia.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed